Abemaciclib plus radiation for liposarcoma before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of the targeted drug abemaciclib and radiation therapy before surgery for people with a specific type of liposarcoma. The goal is to see if this combination can shrink the tumor and help make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a liposarcoma that has a specific genetic change (CDK4 or MDM2 amplification).
- Your tumor must be able to be removed by surgery, and you plan to have radiation therapy before surgery.
- You need to be in good overall health, with adequate blood counts, liver and kidney function, and an ECOG performance status of 0 or 1 (meaning you can do your daily activities).
- You cannot have had chemotherapy or other cancer drugs for this diagnosis, or radiation to the same area before.
- You cannot have a history of blood clots in the last year, or certain heart rhythm problems, or use blood thinners for treatment of prior clots.
- You must not be pregnant or breastfeeding, and you must agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
This trial tests a first-line treatment for people with advanced or unresectable dedifferentiated liposarcoma that has spread. The goal is to find a therapy that works before other treatments are used.
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
Hear when a new Retroperitoneal Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.